Canerpaturev

N/A

Report date: 2022/05/17 11:54:18

Base Information

Drug NameCanerpaturev
Drug Alias NameC-REVCanerpaturev (Takara Bio)HF-10Msc-2TBI-1401
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesThe University Of UtahM'S Science CorporationNagoya University +[5] 
China Registration ClassN/A

Develop Information

Active CompaniesTakara Bio IncTasly Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsMelanoma
Inactive IndicationsSolid tumoursHead and Neck NeoplasmsBreast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A